IVD Reagents Market: Growth, Size, Share, and Trends

Report Code MD 9227
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

IVD Reagents Market by Type (Antibodies, Nucleic Acid Probes), technology (Hematology), Application (Genetic Testing, Autoimmune disease), Test Type (Laboratory Test, Point-of-care Tests), End User (Hospitals & Clinics) & Region - Global Forecast to 2029

Overview

The global IVD reagents market is projected to reach USD 87.4 million by 2029 from USD 60.4 million in 2024, at a CAGR of 7.7% during the forecast period. Growth in the IVD reagents market is primarily driven by innovations in molecular diagnostics focused on improved diagnostic accuracy. The rising awareness of preventive healthcare for early detection contributes to the growth of the market. The growing number of chronic conditions is another key factor driving market growth.

IVD Reagents Market

Attractive Opportunities in the IVD Reagents Market

Asia Pacific

The key factor driving the market include the booming biotechnology and biopharmaceutical industries.

Growth in this market can be attributed to the rapidly increasing geriatric population in Asian countries and the increasing number of hospitals and clinical diagnostic laboratories.

Increasing investment by government agencies are expected to offer lucrative growth opportunities for market players.

The North American IVD reagents market is projected to reach USD 32.7 billion by 2029, growing at a CAGR of 6.8% during the forecast period.

The Asia Pacific market is expected to grow at the highest CAGR of 10.0% during the forecast period.

Global IVD Reagents Market Dynamics

DRIVER: Gradual shift toward point-of-care testing and automated analyzers

The amount of testing conducted outside traditional laboratories is expected to grow in the coming years, driven by the increasing demand for delivering care closer to patients. The range of tests available through point-of-care (POC) testing reagents has significantly expanded recently. For example, immunoassay-based POC testing analyzers offer high sensitivity while ensuring patient compliance. Additionally, these systems help reduce the time needed to diagnose and manage various diseases, such as HIV, malaria, dengue, tuberculosis, and hepatitis C. As a result of these benefits, POC testing products are becoming more widely used to support informed clinical decisions and improve healthcare outcomes.

RESTRAINT: Stringent regulatory requirements

Regulatory and legal requirements applied to IVD (including infectious disease diagnostics) in the US and European countries are becoming more stringent. In the US, IVD products are defined under 21 CFR 809 and regulated under guidelines similar to medical reagents. The FDA released new FDA guidance documents. Under US federal regulations, device manufacturers must submit a 510(k) application for further modifications to a device. New applications may require software updates and installations in an existing device or any other changes made to these reagents.

The EU has moved from Directive 98/79/EC and several earlier directives to the In Vitro Diagnostic Regulation (IVDR) (Regulation (EU) 2017/746), and products must be (Conformité Européenne) CE-marked to be legally marketed in the EU according to the new regulatory framework. The IVDR had a transition period which ended on May 26, 2022, and it went into force on May 26, 2017. The time frame required for regulatory approval for some IVD is uncertain, and investments made in R&D may go in vain if the regulatory authority denies approval.

 

OPPORTUNITY: Rising significance of companion diagnostics

Companion diagnostics include tests or assays intended to assist healthcare providers in making treatment decisions for patients based on the best response to therapy. The co-development of companion diagnostics with therapeutic products can significantly alter the drug development process and commercialize drug candidates by yielding safer drugs with enhanced therapeutic efficacy quickly and cost-effectively. With the increased demand for high-priced specialist therapies and safer drugs, the market for companion diagnostics has high growth potential. The growing importance of companion diagnostics also provides growth opportunities for the diagnostics segment and, in turn, the IVD reagents market.

CHALLENGES: Operational challenges in clinical process

Due to the rapid mutation of microbes and the increasing outbreak of epidemics, clinical laboratories need to adopt innovative technologies capable of rapid sample diagnosis. However, the shortage of skilled laboratory technicians to operate advanced diagnostic products has hindered overall adoption, particularly in emerging markets. In addition, a reluctance to move from manual operations toward automation is another challenge for market growth. Many providers find it difficult to transition to IT-based approaches from manual or traditional ones or may not prefer to make the shift.

Global IVD Reagents Market Ecosystem Analysis

The ecosystem analysis portrays the elements present in the IVD reagents market to understand the interrelated components of a particular market, which thoroughly affects the market. The stakeholders of IVD reagents comprise focused areas such as end users and applications. The IVD reagents market is divided into four segments: type of reagent, application, technology, test type, and end user.

IVD Reagents Market
 

By type, the antibodies segment is projected to register the highest share during the forecast period.

Based on type, the global IVD reagents market is segmented into antibodies, antigens, purified proteins & peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. Antibodies have vast applications in clinical settings, specifically for autoimmune disorders and oncology. Some of the key players offering antibodies include BD (US), Revvity (US), Grifols, S.A. (Spain), among others. The high share of antibodies in the IVD reagents market is due to improved accuracy and higher sensitivity in tailored diagnostics.

By end user, the clinical laboratories segment is projected to register the highest CAGR during the forecast period.

Based on end users, the IVD reagents market is segmented into hospitals & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users. Clinical laboratories are involved in performing diagnostic tests to identify and detect the disease and its respective treatment. The high market growth is attributed to the growing number of diagnostic tests for infectious diseases, hematology, clinical chemistry, immunology, and pathology.

In 2023, North America accounted for the largest share of the IVD reagents market, followed by Europe.

The global IVD reagents market is segmented into six major regions: North America, Europe, the Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. In 2023, North America was the largest segment of the IVD reagents market. The presence of key IVD reagents manufacturers in this region is a key factor driving the market growth. The reimbursement scenario is also less complicated for IVD reagents. The increasing prevalence of diseases in the region is also expected to drive the growth of the IVD reagents market in the US and Canada.

HIGHEST CAGR MARKET IN 2023
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION
IVD Reagents Market

Recent Developments of IVD Reagents Market

  • In September 2024, Thermo Fisher Scientific Inc. (US) introduced a testing/laboratory center for advanced lab services and instrumentation for pharma development worldwide.
  • In December 2023, Danaher Corporation (US) acquired Abcam (UK) to grow its biological segment, which is critical for advancing drug discovery, life sciences research, and diagnostics.
  • In December 2023, F. Hoffmann-La Roche Ltd (Switzerland) entered into a definitive agreement to acquire LumiraDx’s (US) point-of-care technology, thus combining multiple diagnostic modalities on a single platform.
  • In May 2022, Hologic, Inc. (US) received CE marking for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion BKV Quant Assay, expanding its transplant pathogen monitoring menu on the Panther Fusion system.

Key Market Players

Want to explore hidden markets that can drive new revenue in IVD Reagents Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD Million)
Segments covered Type, technology, application, test type, and end user.
Geographies covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and the GCC Countries

 

Key Questions Addressed by the Report

What are the recent trends driving the IVD reagents market?
The recent trends include the growing geriatric population, a rise in early diagnosis and personalized medicine, and a gradual shift toward point-of-care testing and automated analyzers in the IVD reagents market.
How vast is the IVD reagents market worldwide?
The IVD reagents market is expected to grow at a CAGR of 7.7% over the forecast period and reach USD 87.4 billion by 2029 from USD 60.4 billion in 2024.
Which type categories are included in the IVD reagents market? Which category of reagent is the market leader?
The IVD reagents market is divided into five segments: antibodies, antigens, purified proteins & peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. In 2023, the antibodies segment commanded the largest share of the market.
Who are the end users of IVD reagents? Which end user will dominate the market?
The IVD reagents market is segmented into hospitals & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users. In 2023, the hospitals & clinics segment accounted for the largest share of the market.
Who are the key players in the IVD reagents market?
The key players in the IVD reagents market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), BioMerieux (France), BD (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), DiaSorin S.p.A (Italy), Grifols, S.A. (Spain), Werfen, S.A. (Spain), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Merck KGaA (Germany), MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Tokyo), Canvax (Spain), Prestige Diagnostics (US), Adaltis S.r.l. (Italy), and Randox Laboratories Ltd. (UK).
Which is the most lucrative region in the IVD reagents market?
The Asia Pacific market is expected to witness the highest growth during the forecast period due to factors such as the increasing number of clinical laboratories in this region and improving healthcare expenditure in Asia Pacific countries.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the IVD Reagents Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
38
RESEARCH METHODOLOGY
42
EXECUTIVE SUMMARY
54
PREMIUM INSIGHTS
59
MARKET OVERVIEW
62
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing geriatric population
    - Gradual shift toward point-of-care testing and automated analyzers
    - Rise in early diagnosis and personalized medicine
    - Increasing adoption of third-party quality controls
    - Growing biotechnology and biopharmaceutical industries
    - Increasing funding for R&D activities
    RESTRAINTS
    - Unfavorable reimbursement scenario
    - Stringent regulatory requirements
    OPPORTUNITIES
    - Increasing development of biomarkers
    - Rising significance of companion diagnostics
    - Market growth opportunities in emerging economies
    - Growing trend of digitalization
    CHALLENGES
    - Operational challenges in clinical process
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION
    AVERAGE SELLING PRICE TREND, BY TECHNOLOGY
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    ADJACENT TECHNOLOGIES
    - Multiplexed point-of-care testing
    - Nucleic acid lateral flow immunoassay
    - DNA-based detection
    - Immunodiagnostics
    - Dual path technology
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA
    EXPORT DATA
  • 5.12 KEY CONFERENCES AND EVENTS, 2024−2025
  • 5.13 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
    - GCC Countries
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.16 IMPACT OF AI/GENERATIVE AI ON IVD REAGENTS MARKET
    INTRODUCTION
    MARKET POTENTIAL FOR IVD REAGENTS
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI
    FUTURE OF GENERATIVE AI ON IVD REAGENTS
IVD REAGENTS MARKET, BY TYPE
101
  • 6.1 INTRODUCTION
  • 6.2 ANTIBODIES
    MONOCLONAL ANTIBODIES
    - Increasing incidence of cancer to stimulate growth
    POLYCLONAL ANTIBODIES
    - Rising prevalence of infectious diseases and autoimmune disorders to support growth
  • 6.3 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
    INCREASING FOCUS ON ADVANCED PRECISION MEDICINE TO ENCOURAGE GROWTH
  • 6.4 OLIGONUCLEOTIDES
    GROWING INCLINATION TOWARD MOLECULAR DIAGNOSTICS TO DRIVE MARKET
  • 6.5 NUCLEIC ACID PROBES
    NEED FOR EARLY DISEASE DETECTION AND MONITORING LOW-ABUNDANCE BIOMARKERS TO AID GROWTH
  • 6.6 OTHER IVD REAGENTS
IVD REAGENTS MARKET, BY TECHNOLOGY
123
  • 7.1 INTRODUCTION
  • 7.2 IMMUNOASSAYS
    RISING TREND OF AUTOMATION TO PROMOTE GROWTH
  • 7.3 CLINICAL CHEMISTRY
    RISING PREVALENCE OF DIABETES TO BOOST SEGMENT
  • 7.4 MOLECULAR DIAGNOSTICS
    GROWING DEMAND FOR BLOOD SCREENING AND POINT-OF-CARE TESTING TO FUEL MARKET
  • 7.5 HEMATOLOGY
    INCREASING FOCUS ON STEM CELL RESEARCH TO SPEED UP GROWTH
  • 7.6 MICROBIOLOGY
    RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET
  • 7.7 COAGULATION & HEMOSTASIS
    GROWING USE OF ANTICOAGULATION THERAPY TO PROPEL MARKET
  • 7.8 URINALYSIS
    RISING PREVALENCE OF KIDNEY DISEASES TO SUPPORT MARKET GROWTH
  • 7.9 CHROMATOGRAPHY & MASS SPECTROMETRY
    INCREASING APPLICATIONS IN DISEASE SCREENING, FORENSIC ANALYSIS, AND DRUG THERAPY TO BOOST MARKET
  • 7.10 IMMUNOHISTOCHEMISTRY
    GROWING NUMBER OF LABORATORY TESTS FOR CANCER DIAGNOSIS TO DRIVE MARKET
IVD REAGENTS MARKET, BY APPLICATION
150
  • 8.1 INTRODUCTION
  • 8.2 INFECTIOUS DISEASES
    INCREASING PRODUCT LAUNCHES AND APPROVALS TO BOOST MARKET
  • 8.3 ONCOLOGICAL APPLICATIONS
    GROWING EMPHASIS ON EARLY DIAGNOSIS AND QUALITY TREATMENT TO FUEL MARKET
  • 8.4 ENDOCRINOLOGICAL APPLICATIONS
    RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS TO SUSTAIN GROWTH
  • 8.5 CARDIOLOGICAL APPLICATIONS
    CHANGING LIFESTYLES IN DEVELOPED AND DEVELOPING COUNTRIES TO PROPEL MARKET
  • 8.6 BLOOD SCREENING
    RISING ADOPTION OF AUTOMATED DIAGNOSTIC INSTRUMENTS TO FACILITATE GROWTH
  • 8.7 GENETIC TESTING
    INCREASING ADOPTION OF GENETIC TESTING TO DIAGNOSE RARE AND FATAL DISEASES TO SUSTAIN GROWTH
  • 8.8 AUTOIMMUNE DISEASES
    GROWING ADVANCEMENTS IN LABORATORY TECHNOLOGY, REAGENTS, AND ALTERNATIVE ASSAY METHODOLOGIES TO DRIVE MARKET
  • 8.9 ALLERGY DIAGNOSTICS
    GROWING FOCUS ON ALLERGY THERAPY AND PREVENTION TO ACCELERATE GROWTH
  • 8.10 DRUG MONITORING & TESTING
    GROWING IMPLEMENTATION OF DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
  • 8.11 OTHER APPLICATIONS
IVD REAGENTS MARKET, BY TEST TYPE
182
  • 9.1 INTRODUCTION
  • 9.2 LABORATORY TESTS
    INCREASING NEED FOR AUTOMATION TO EXPEDITE GROWTH
  • 9.3 POINT-OF-CARE TESTS
    NEED TO CLOSELY MONITOR PATIENT CONDITIONS TO AUGMENT GROWTH
IVD REAGENTS MARKET, BY END USER
190
  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS & CLINICS
    INCREASING SPECIALTY DIAGNOSTIC TESTS TO ACCELERATE GROWTH
  • 10.3 CLINICAL LABORATORIES
    LARGE REFERENCE LABORATORIES
    - Need for specialized testing capabilities and minimal turnaround time to boost market
    SMALL & MEDIUM-SIZED LABORATORIES
    - Growing adoption of automated and semi-automated instruments to support growth
  • 10.4 BLOOD BANKS
    GROWING NUMBER OF TRAUMA CASES AND AVAILABILITY OF SOPHISTICATED SURGICAL PROCEDURES TO FUEL MARKET
  • 10.5 HOME CARE SETTINGS
    GROWING PREFERENCE FOR AT-HOME TESTING KITS TO DRIVE MARKET
  • 10.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INCREASING RESEARCH & DEVELOPMENT EFFORTS TO CONTRIBUTE TO GROWTH
  • 10.7 ACADEMIC INSTITUTES
    INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO FAVOR GROWTH
  • 10.8 OTHER END USERS
IVD REAGENTS MARKET, BY REGION
219
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Established reimbursement framework to drive market
    CANADA
    - Rising incidence of chronic and infectious lifestyle diseases to propel market
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increasing investments in clinical diagnostics research to drive market
    UK
    - Rising adoption of genome-based testing to promote growth
    FRANCE
    - High healthcare expenditure and rising investments in genomic medicine to boost market
    ITALY
    - Growing geriatric population and subsequent rise in chronic conditions to support market growth
    SPAIN
    - Rising adoption of immunoassay reagents to drive market
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    - Rise in social health insurance programs to encourage growth
    CHINA
    - Growing focus on preventive care to boost demand
    INDIA
    - Rising prevalence of chronic diseases to fuel market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Rising prevalence of diabetes to stimulate growth
    MEXICO
    - Growing establishment of clinical laboratories to boost market
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    GROWING FOCUS ON IMMUNOLOGY AND PRENATAL & CANCER TESTING TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.7 GCC COUNTRIES
    MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
    KINGDOM OF SAUDI ARABIA
    - Rising healthcare expenditure to promote growth
    UNITED ARAB EMIRATES
    - Increasing development of advanced healthcare infrastructure to expedite growth
    OTHER GCC COUNTRIES
COMPETITIVE LANDSCAPE
318
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021–2023
  • 12.3 REVENUE ANALYSIS, 2021−2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
  • 12.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.6 BRAND/PRODUCT COMPARISON
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Technology footprint
    - Application footprint
    - Test type footprint
    - Region footprint
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
338
  • 13.1 KEY PLAYERS
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ABBOTT
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ILLUMINA, INC.
    - Business overview
    - Products offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    BD
    - Business overview
    - Products offered
    - Recent developments
    HOLOGIC, INC.
    - Business overview
    - Products offered
    - Recent developments
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products offered
    - Recent developments
    SYSMEX CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    QIAGEN N.V.
    - Business overview
    - Products offered
    - Recent developments
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products offered
    - Recent developments
    REVVITY
    - Business overview
    - Products offered
    - Recent developments
    DIASORIN S.P.A.
    - Business overview
    - Products offered
    - Recent developments
    GRIFOLS, S.A.
    - Business overview
    - Products offered
    - Recent developments
    WERFEN, S.A.
    - Business overview
    - Products offered
    - Recent developments
    QUIDELORTHO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    CHEMBIO DIAGNOSTICS, INC.
    - Business overview
    - Products offered
    SURMODICS, INC.
    - Business overview
    - Products offered
    MERCK KGAA
    - Business overview
    - Products offered
  • 13.2 OTHER PLAYERS
    MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
    CANVAX
    PRESTIGE DIAGNOSTICS
    ADALTIS S.R.L.
    RANDOX LABORATORIES LTD.
APPENDIX
415
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLE
416
  • 15.1 TABLE 1 IVD REAGENTS MARKET: INCLUSIONS AND EXCLUSIONS
  • 15.2 TABLE 2 IVD REAGENTS MARKET: RISK ASSESSMENT
  • 15.3 TABLE 3 ESTIMATED INCREASE IN GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050
  • 15.4 TABLE 4 RECENT DEVELOPMENTS IN IVD REAGENTS MARKET IN EMERGING ECONOMIES, 2022–2023
  • 15.5 TABLE 5 AVERAGE SELLING PRICE TREND OF KEY PLAYERS FOR TOP 2 APPLICATIONS, 2021–2023 (USD)
  • 15.6 TABLE 6 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION, 2021–2023 (USD)
  • 15.7 TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2021–2023 (USD)
  • 15.8 TABLE 8 IVD REAGENTS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • 15.9 TABLE 9 IVD REAGENTS MARKET: KEY TECHNOLOGIES
  • 15.10 TABLE 10 IMPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2023 (USD MILLION)
  • 15.11 TABLE 11 EXPORT DATA FOR HS CODE 382200, BY COUNTRY, 2019–2023 (USD MILLION)
  • 15.12 TABLE 12 IVD REAGENTS MARKET: KEY CONFERENCES AND EVENTS, 2024−2025
  • 15.13 TABLE 13 IVD REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • 15.14 TABLE 14 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL FOR IVD REAGENTS
  • 15.15 TABLE 15 US: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • 15.16 TABLE 16 CANADA: CLASSIFICATION OF IVD PRODUCTS
  • 15.17 TABLE 17 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • 15.18 TABLE 18 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
  • 15.19 TABLE 19 EUROPE: CLASSIFICATION OF IVD REAGENTS
  • 15.20 TABLE 20 EUROPE: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • 15.21 TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • 15.22 TABLE 22 JAPAN: CLASSIFICATION OF IVD REAGENTS
  • 15.23 TABLE 23 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION FOR IVD REAGENTS
  • 15.24 TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 15.25 TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 15.26 TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 15.27 TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 15.28 TABLE 28 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 15.29 TABLE 29 GCC COUNTRIES: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 15.30 TABLE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER (%)
  • 15.31 TABLE 31 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER
  • 15.32 TABLE 32 IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.33 TABLE 33 COMPANIES PROVIDING ANTIBODIES
  • 15.34 TABLE 34 ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.35 TABLE 35 ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.36 TABLE 36 NORTH AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.37 TABLE 37 EUROPE: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.38 TABLE 38 ASIA PACIFIC: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.39 TABLE 39 LATIN AMERICA: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.40 TABLE 40 GCC COUNTRIES: ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.41 TABLE 41 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.42 TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.43 TABLE 43 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.44 TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.45 TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.46 TABLE 46 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.47 TABLE 47 POLYCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.48 TABLE 48 NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.49 TABLE 49 EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.50 TABLE 50 ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.51 TABLE 51 LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.52 TABLE 52 GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.53 TABLE 53 COMPANIES PROVIDING ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES
  • 15.54 TABLE 54 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.55 TABLE 55 NORTH AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.56 TABLE 56 EUROPE: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.57 TABLE 57 ASIA PACIFIC: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.58 TABLE 58 LATIN AMERICA: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.59 TABLE 59 GCC COUNTRIES: ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.60 TABLE 60 COMPANIES PROVIDING OLIGONUCLEOTIDES
  • 15.61 TABLE 61 OLIGONUCLEOTIDES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.62 TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.63 TABLE 63 EUROPE: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.64 TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.65 TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.66 TABLE 66 GCC COUNTRIES: OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.67 TABLE 67 COMPANIES PROVIDING NUCLEIC ACID PROBES
  • 15.68 TABLE 68 NUCLEIC ACID PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.69 TABLE 69 NORTH AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.70 TABLE 70 EUROPE: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.71 TABLE 71 ASIA PACIFIC: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.72 TABLE 72 LATIN AMERICA: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.73 TABLE 73 GCC COUNTRIES: NUCLEIC ACID PROBES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.74 TABLE 74 COMPANIES PROVIDING OTHER IVD REAGENTS
  • 15.75 TABLE 75 OTHER IVD REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.76 TABLE 76 NORTH AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.77 TABLE 77 EUROPE: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.78 TABLE 78 ASIA PACIFIC: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.79 TABLE 79 LATIN AMERICA: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.80 TABLE 80 GCC COUNTRIES: OTHER IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.81 TABLE 81 IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.82 TABLE 82 IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY REGION, 2022–2029 (USD MILLION)
  • 15.83 TABLE 83 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.84 TABLE 84 EUROPE: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.85 TABLE 85 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.86 TABLE 86 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.87 TABLE 87 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.88 TABLE 88 IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
  • 15.89 TABLE 89 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.90 TABLE 90 EUROPE: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.91 TABLE 91 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.92 TABLE 92 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.93 TABLE 93 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.94 TABLE 94 IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)
  • 15.95 TABLE 95 NORTH AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.96 TABLE 96 EUROPE: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.97 TABLE 97 ASIA PACIFIC: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.98 TABLE 98 LATIN AMERICA: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.99 TABLE 99 GCC COUNTRIES: IVD REAGENTS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.100 TABLE 100 IVD REAGENTS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • 15.101 TABLE 101 NORTH AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.102 TABLE 102 EUROPE: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.103 TABLE 103 ASIA PACIFIC: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.104 TABLE 104 LATIN AMERICA: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.105 TABLE 105 GCC COUNTRIES: IVD REAGENTS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.106 TABLE 106 IVD REAGENTS MARKET FOR MICROBIOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • 15.107 TABLE 107 NORTH AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.108 TABLE 108 EUROPE: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.109 TABLE 109 ASIA PACIFIC: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.110 TABLE 110 LATIN AMERICA: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.111 TABLE 111 GCC COUNTRIES: IVD REAGENTS MARKET FOR MICROBIOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.112 TABLE 112 IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY REGION, 2022–2029 (USD MILLION)
  • 15.113 TABLE 113 NORTH AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.114 TABLE 114 EUROPE: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.115 TABLE 115 ASIA PACIFIC: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.116 TABLE 116 LATIN AMERICA: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.117 TABLE 117 GCC COUNTRIES: IVD REAGENTS MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.118 TABLE 118 IVD REAGENTS MARKET FOR URINALYSIS, BY REGION, 2022–2029 (USD MILLION)
  • 15.119 TABLE 119 NORTH AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.120 TABLE 120 EUROPE: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.121 TABLE 121 ASIA PACIFIC: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.122 TABLE 122 LATIN AMERICA: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.123 TABLE 123 GCC COUNTRIES: IVD REAGENTS MARKET FOR URINALYSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.124 TABLE 124 IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
  • 15.125 TABLE 125 NORTH AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.126 TABLE 126 EUROPE: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.127 TABLE 127 ASIA PACIFIC: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.128 TABLE 128 LATIN AMERICA: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.129 TABLE 129 GCC COUNTRIES: IVD REAGENTS MARKET FOR CHROMATOGRAPHY & MASS SPECTROMETRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.130 TABLE 130 IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
  • 15.131 TABLE 131 NORTH AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.132 TABLE 132 EUROPE: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.133 TABLE 133 ASIA PACIFIC: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.134 TABLE 134 LATIN AMERICA: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.135 TABLE 135 GCC COUNTRIES: IVD REAGENTS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.136 TABLE 136 IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.137 TABLE 137 IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • 15.138 TABLE 138 NORTH AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.139 TABLE 139 EUROPE: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.140 TABLE 140 ASIA PACIFIC: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.141 TABLE 141 LATIN AMERICA: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.142 TABLE 142 GCC COUNTRIES: IVD REAGENTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.143 TABLE 143 ESTIMATED NUMBER OF NEW CASES OF CANCER FOR 0–85+ YEARS OF AGE, 2022 VS. 2030
  • 15.144 TABLE 144 IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • 15.145 TABLE 145 NORTH AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.146 TABLE 146 EUROPE: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.147 TABLE 147 ASIA PACIFIC: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.148 TABLE 148 LATIN AMERICA: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.149 TABLE 149 GCC COUNTRIES: IVD REAGENTS MARKET FOR ONCOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.150 TABLE 150 IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • 15.151 TABLE 151 NORTH AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.152 TABLE 152 EUROPE: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.153 TABLE 153 ASIA PACIFIC: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.154 TABLE 154 LATIN AMERICA: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.155 TABLE 155 GCC COUNTRIES: IVD REAGENTS MARKET FOR ENDOCRINOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.156 TABLE 156 IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • 15.157 TABLE 157 NORTH AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.158 TABLE 158 EUROPE: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.159 TABLE 159 ASIA PACIFIC: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.160 TABLE 160 LATIN AMERICA: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.161 TABLE 161 GCC COUNTRIES: IVD REAGENTS MARKET FOR CARDIOLOGICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.162 TABLE 162 IVD REAGENTS MARKET FOR BLOOD SCREENING, BY REGION, 2022–2029 (USD MILLION)
  • 15.163 TABLE 163 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.164 TABLE 164 EUROPE: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.165 TABLE 165 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.166 TABLE 166 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.167 TABLE 167 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD SCREENING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.168 TABLE 168 IVD REAGENTS MARKET FOR GENETIC TESTING, BY REGION, 2022–2029 (USD MILLION)
  • 15.169 TABLE 169 NORTH AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.170 TABLE 170 EUROPE: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.171 TABLE 171 ASIA PACIFIC: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.172 TABLE 172 LATIN AMERICA: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.173 TABLE 173 GCC COUNTRIES: IVD REAGENTS MARKET FOR GENETIC TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.174 TABLE 174 IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • 15.175 TABLE 175 NORTH AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.176 TABLE 176 EUROPE: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.177 TABLE 177 ASIA PACIFIC: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.178 TABLE 178 LATIN AMERICA: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.179 TABLE 179 GCC COUNTRIES: IVD REAGENTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.180 TABLE 180 IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION)
  • 15.181 TABLE 181 NORTH AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.182 TABLE 182 EUROPE: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.183 TABLE 183 ASIA PACIFIC: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.184 TABLE 184 LATIN AMERICA: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.185 TABLE 185 GCC COUNTRIES: IVD REAGENTS MARKET FOR ALLERGY DIAGNOSTICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.186 TABLE 186 KEY PRODUCTS FOR DRUG MONITORING
  • 15.187 TABLE 187 IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY REGION, 2022–2029 (USD MILLION)
  • 15.188 TABLE 188 NORTH AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.189 TABLE 189 EUROPE: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.190 TABLE 190 ASIA PACIFIC: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.191 TABLE 191 LATIN AMERICA: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.192 TABLE 192 GCC COUNTRIES: IVD REAGENTS MARKET FOR DRUG MONITORING & TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.193 TABLE 193 IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • 15.194 TABLE 194 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.195 TABLE 195 EUROPE: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.196 TABLE 196 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.197 TABLE 197 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.198 TABLE 198 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.199 TABLE 199 IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.200 TABLE 200 IVD REAGENTS MARKET FOR LABORATORY TESTS, BY REGION, 2022–2029 (USD MILLION)
  • 15.201 TABLE 201 NORTH AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.202 TABLE 202 EUROPE: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.203 TABLE 203 ASIA PACIFIC: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.204 TABLE 204 LATIN AMERICA: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.205 TABLE 205 GCC COUNTRIES: IVD REAGENTS MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.206 TABLE 206 IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY REGION, 2022–2029 (USD MILLION)
  • 15.207 TABLE 207 NORTH AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.208 TABLE 208 EUROPE: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.209 TABLE 209 ASIA PACIFIC: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.210 TABLE 210 LATIN AMERICA: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.211 TABLE 211 GCC COUNTRIES: IVD REAGENTS MARKET FOR POINT-OF-CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.212 TABLE 212 IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.213 TABLE 213 IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
  • 15.214 TABLE 214 NORTH AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.215 TABLE 215 EUROPE: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.216 TABLE 216 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.217 TABLE 217 LATIN AMERICA: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.218 TABLE 218 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.219 TABLE 219 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • 15.220 TABLE 220 IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY TYPE, 2022–2029 (USD MILLION)
  • 15.221 TABLE 221 NORTH AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.222 TABLE 222 EUROPE: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.223 TABLE 223 ASIA PACIFIC: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.224 TABLE 224 LATIN AMERICA: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.225 TABLE 225 GCC COUNTRIES: IVD REAGENTS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.226 TABLE 226 IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • 15.227 TABLE 227 NORTH AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.228 TABLE 228 EUROPE: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.229 TABLE 229 ASIA PACIFIC: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.230 TABLE 230 LATIN AMERICA: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.231 TABLE 231 GCC COUNTRIES: IVD REAGENTS MARKET FOR LARGE REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.232 TABLE 232 IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • 15.233 TABLE 233 NORTH AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.234 TABLE 234 EUROPE: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.235 TABLE 235 ASIA PACIFIC: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.236 TABLE 236 LATIN AMERICA: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.237 TABLE 237 GCC COUNTRIES: IVD REAGENTS MARKET FOR SMALL & MEDIUM LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.238 TABLE 238 IVD REAGENTS MARKET FOR BLOOD BANKS, BY REGION, 2022–2029 (USD MILLION)
  • 15.239 TABLE 239 NORTH AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.240 TABLE 240 EUROPE: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.241 TABLE 241 ASIA PACIFIC: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.242 TABLE 242 LATIN AMERICA: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.243 TABLE 243 GCC COUNTRIES: IVD REAGENTS MARKET FOR BLOOD BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.244 TABLE 244 IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2029 (USD MILLION)
  • 15.245 TABLE 245 NORTH AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.246 TABLE 246 EUROPE: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.247 TABLE 247 ASIA PACIFIC: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.248 TABLE 248 LATIN AMERICA: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.249 TABLE 249 GCC COUNTRIES: IVD REAGENTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.250 TABLE 250 IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • 15.251 TABLE 251 NORTH AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.252 TABLE 252 EUROPE: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.253 TABLE 253 ASIA PACIFIC: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.254 TABLE 254 LATIN AMERICA: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.255 TABLE 255 GCC COUNTRIES: IVD REAGENTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.256 TABLE 256 IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
  • 15.257 TABLE 257 NORTH AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.258 TABLE 258 EUROPE: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.259 TABLE 259 ASIA PACIFIC: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.260 TABLE 260 LATIN AMERICA: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.261 TABLE 261 GCC COUNTRIES: IVD REAGENTS MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.262 TABLE 262 IVD REAGENTS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • 15.263 TABLE 263 NORTH AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.264 TABLE 264 EUROPE: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.265 TABLE 265 ASIA PACIFIC: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.266 TABLE 266 LATIN AMERICA: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.267 TABLE 267 GCC COUNTRIES: IVD REAGENTS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.268 TABLE 268 IVD REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • 15.269 TABLE 269 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN NORTH AMERICA
  • 15.270 TABLE 270 NORTH AMERICA: MACROECONOMIC INDICATORS
  • 15.271 TABLE 271 NORTH AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.272 TABLE 272 NORTH AMERICA: IVD TESTS CONDUCTED, BY COUNTRY, 2022–2029 (BILLION UNIT)
  • 15.273 TABLE 273 NORTH AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.274 TABLE 274 NORTH AMERICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.275 TABLE 275 NORTH AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.276 TABLE 276 NORTH AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.277 TABLE 277 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.278 TABLE 278 NORTH AMERICA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.279 TABLE 279 NORTH AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.280 TABLE 280 US: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.281 TABLE 281 US: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.282 TABLE 282 US: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.283 TABLE 283 US: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.284 TABLE 284 US: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.285 TABLE 285 US: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.286 TABLE 286 US: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.287 TABLE 287 CANADA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.288 TABLE 288 CANADA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.289 TABLE 289 CANADA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.290 TABLE 290 CANADA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.291 TABLE 291 CANADA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.292 TABLE 292 CANADA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.293 TABLE 293 CANADA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.294 TABLE 294 KEY IVD REAGENTS PROVIDED BY MAJOR PLAYERS IN EUROPE
  • 15.295 TABLE 295 EUROPE: MACROECONOMIC INDICATORS
  • 15.296 TABLE 296 EUROPE: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.297 TABLE 297 EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.298 TABLE 298 EUROPE: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.299 TABLE 299 EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.300 TABLE 300 EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.301 TABLE 301 EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.302 TABLE 302 EUROPE: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.303 TABLE 303 EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.304 TABLE 304 GERMANY: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.305 TABLE 305 GERMANY: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.306 TABLE 306 GERMANY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.307 TABLE 307 GERMANY: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.308 TABLE 308 GERMANY: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.309 TABLE 309 GERMANY: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.310 TABLE 310 GERMANY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.311 TABLE 311 UK: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.312 TABLE 312 UK: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.313 TABLE 313 UK: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.314 TABLE 314 UK: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.315 TABLE 315 UK: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.316 TABLE 316 UK: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.317 TABLE 317 UK: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.318 TABLE 318 FRANCE: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.319 TABLE 319 FRANCE: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.320 TABLE 320 FRANCE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.321 TABLE 321 FRANCE: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.322 TABLE 322 FRANCE: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.323 TABLE 323 FRANCE: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.324 TABLE 324 FRANCE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.325 TABLE 325 ITALY: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.326 TABLE 326 ITALY: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.327 TABLE 327 ITALY: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.328 TABLE 328 ITALY: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.329 TABLE 329 ITALY: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.330 TABLE 330 ITALY: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.331 TABLE 331 ITALY: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.332 TABLE 332 SPAIN: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.333 TABLE 333 SPAIN: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.334 TABLE 334 SPAIN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.335 TABLE 335 SPAIN: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.336 TABLE 336 SPAIN: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.337 TABLE 337 SPAIN: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.338 TABLE 338 SPAIN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.339 TABLE 339 REST OF EUROPE: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.340 TABLE 340 REST OF EUROPE: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.341 TABLE 341 REST OF EUROPE: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.342 TABLE 342 REST OF EUROPE: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.343 TABLE 343 REST OF EUROPE: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.344 TABLE 344 REST OF EUROPE: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.345 TABLE 345 REST OF EUROPE: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.346 TABLE 346 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • 15.347 TABLE 347 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.348 TABLE 348 ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.349 TABLE 349 ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.350 TABLE 350 ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.351 TABLE 351 ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.352 TABLE 352 ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.353 TABLE 353 ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.354 TABLE 354 ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.355 TABLE 355 JAPAN: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.356 TABLE 356 JAPAN: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.357 TABLE 357 JAPAN: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.358 TABLE 358 JAPAN: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.359 TABLE 359 JAPAN: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.360 TABLE 360 JAPAN: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.361 TABLE 361 JAPAN: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.362 TABLE 362 CHINA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.363 TABLE 363 CHINA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.364 TABLE 364 CHINA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.365 TABLE 365 CHINA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.366 TABLE 366 CHINA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.367 TABLE 367 CHINA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.368 TABLE 368 CHINA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.369 TABLE 369 INDIA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.370 TABLE 370 INDIA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.371 TABLE 371 INDIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.372 TABLE 372 INDIA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.373 TABLE 373 INDIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.374 TABLE 374 INDIA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.375 TABLE 375 INDIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.376 TABLE 376 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.377 TABLE 377 REST OF ASIA PACIFIC: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.378 TABLE 378 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.379 TABLE 379 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.380 TABLE 380 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.381 TABLE 381 REST OF ASIA PACIFIC: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.382 TABLE 382 REST OF ASIA PACIFIC: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.383 TABLE 383 LATIN AMERICA: MACROECONOMIC INDICATORS
  • 15.384 TABLE 384 LATIN AMERICA: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.385 TABLE 385 LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.386 TABLE 386 LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.387 TABLE 387 LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.388 TABLE 388 LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.389 TABLE 389 LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.390 TABLE 390 LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.391 TABLE 391 LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.392 TABLE 392 BRAZIL: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.393 TABLE 393 BRAZIL: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.394 TABLE 394 BRAZIL: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.395 TABLE 395 BRAZIL: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.396 TABLE 396 BRAZIL: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.397 TABLE 397 BRAZIL: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.398 TABLE 398 BRAZIL: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.399 TABLE 399 MEXICO: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.400 TABLE 400 MEXICO: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.401 TABLE 401 MEXICO: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.402 TABLE 402 MEXICO: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.403 TABLE 403 MEXICO: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.404 TABLE 404 MEXICO: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.405 TABLE 405 MEXICO: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.406 TABLE 406 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.407 TABLE 407 REST OF LATIN AMERICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.408 TABLE 408 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.409 TABLE 409 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.410 TABLE 410 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.411 TABLE 411 REST OF LATIN AMERICA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.412 TABLE 412 REST OF LATIN AMERICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.413 TABLE 413 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • 15.414 TABLE 414 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.415 TABLE 415 MIDDLE EAST & AFRICA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.416 TABLE 416 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.417 TABLE 417 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.418 TABLE 418 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.419 TABLE 419 MIDDLE EAST & AFRICA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.420 TABLE 420 MIDDLE EAST & AFRICA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.421 TABLE 421 GCC COUNTRIES: MACROECONOMIC INDICATORS
  • 15.422 TABLE 422 GCC COUNTRIES: IVD REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • 15.423 TABLE 423 GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.424 TABLE 424 GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.425 TABLE 425 GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.426 TABLE 426 GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.427 TABLE 427 GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.428 TABLE 428 GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.429 TABLE 429 GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.430 TABLE 430 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.431 TABLE 431 KINGDOM OF SAUDI ARABIA: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.432 TABLE 432 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.433 TABLE 433 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.434 TABLE 434 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.435 TABLE 435 KINGDOM OF SAUDI ARABIA: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.436 TABLE 436 KINGDOM OF SAUDI ARABIA: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.437 TABLE 437 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.438 TABLE 438 UNITED ARAB EMIRATES: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.439 TABLE 439 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.440 TABLE 440 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.441 TABLE 441 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.442 TABLE 442 UNITED ARAB EMIRATES: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.443 TABLE 443 UNITED ARAB EMIRATES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.444 TABLE 444 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.445 TABLE 445 OTHER GCC COUNTRIES: ANTIBODIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.446 TABLE 446 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • 15.447 TABLE 447 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • 15.448 TABLE 448 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • 15.449 TABLE 449 OTHER GCC COUNTRIES: IVD REAGENTS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • 15.450 TABLE 450 OTHER GCC COUNTRIES: CLINICAL LABORATORIES MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • 15.451 TABLE 451 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS MARKET, 2021–2023
  • 15.452 TABLE 452 IVD REAGENTS MARKET: DEGREE OF COMPETITION
  • 15.453 TABLE 453 IVD REAGENTS MARKET: TECHNOLOGY FOOTPRINT
  • 15.454 TABLE 454 IVD REAGENTS MARKET: APPLICATION FOOTPRINT
  • 15.455 TABLE 455 IVD REAGENTS MARKET: TEST TYPE FOOTPRINT
  • 15.456 TABLE 456 IVD REAGENTS MARKET: REGION FOOTPRINT
  • 15.457 TABLE 457 IVD REAGENTS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • 15.458 TABLE 458 IVD REAGENTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 15.459 TABLE 459 IVD REAGENTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–SEPTEMBER 2024
  • 15.460 TABLE 460 IVD REAGENTS MARKET: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.461 TABLE 461 IVD REAGENTS MARKET: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • 15.462 TABLE 462 IVD REAGENTS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024
  • 15.463 TABLE 463 DANAHER CORPORATION: COMPANY OVERVIEW
  • 15.464 TABLE 464 DANAHER CORPORATION: PRODUCTS OFFERED
  • 15.465 TABLE 465 DANAHER CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.466 TABLE 466 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • 15.467 TABLE 467 DANAHER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024
  • 15.468 TABLE 468 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • 15.469 TABLE 469 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • 15.470 TABLE 470 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.471 TABLE 471 ABBOTT: COMPANY OVERVIEW
  • 15.472 TABLE 472 ABBOTT: PRODUCTS OFFERED
  • 15.473 TABLE 473 ABBOTT: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.474 TABLE 474 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • 15.475 TABLE 475 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • 15.476 TABLE 476 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.477 TABLE 477 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • 15.478 TABLE 478 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • 15.479 TABLE 479 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.480 TABLE 480 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • 15.481 TABLE 481 ILLUMINA, INC.: COMPANY OVERVIEW
  • 15.482 TABLE 482 ILLUMINA, INC.: PRODUCTS OFFERED
  • 15.483 TABLE 483 ILLUMINA, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.484 TABLE 484 BIOMÉRIEUX: COMPANY OVERVIEW
  • 15.485 TABLE 485 BIOMÉRIEUX: PRODUCTS OFFERED
  • 15.486 TABLE 486 BIOMÉRIEUX: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.487 TABLE 487 BD: COMPANY OVERVIEW
  • 15.488 TABLE 488 BD: PRODUCTS OFFERED
  • 15.489 TABLE 489 BD: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.490 TABLE 490 HOLOGIC, INC.: COMPANY OVERVIEW
  • 15.491 TABLE 491 HOLOGIC, INC.: PRODUCTS OFFERED
  • 15.492 TABLE 492 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–SEPTEMBER 2024
  • 15.493 TABLE 493 HOLOGIC, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.494 TABLE 494 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • 15.495 TABLE 495 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • 15.496 TABLE 496 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.497 TABLE 497 SYSMEX CORPORATION: COMPANY OVERVIEW
  • 15.498 TABLE 498 SYSMEX CORPORATION: PRODUCTS OFFERED
  • 15.499 TABLE 499 SYSMEX CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–SEPTEMBER 2024
  • 15.500 TABLE 500 SYSMEX CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.501 TABLE 501 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • 15.502 TABLE 502 QIAGEN N.V.: COMPANY OVERVIEW
  • 15.503 TABLE 503 QIAGEN N.V.: PRODUCTS OFFERED
  • 15.504 TABLE 504 QIAGEN N.V.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.505 TABLE 505 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • 15.506 TABLE 506 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
  • 15.507 TABLE 507 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.508 TABLE 508 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • 15.509 TABLE 509 REVVITY: COMPANY OVERVIEW
  • 15.510 TABLE 510 REVVITY: PRODUCTS OFFERED
  • 15.511 TABLE 511 REVVITY: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.512 TABLE 512 REVVITY: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024
  • 15.513 TABLE 513 DIASORIN S.P.A.: COMPANY OVERVIEW
  • 15.514 TABLE 514 DIASORIN S.P.A.: PRODUCTS OFFERED
  • 15.515 TABLE 515 DIASORIN S.P.A.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.516 TABLE 516 GRIFOLS S.A.: COMPANY OVERVIEW
  • 15.517 TABLE 517 GRIFOLS S.A.: PRODUCTS OFFERED
  • 15.518 TABLE 518 GRIFOLS S.A.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.519 TABLE 519 WERFEN, S.A.: COMPANY OVERVIEW
  • 15.520 TABLE 520 WERFEN, S.A.: PRODUCTS OFFERED
  • 15.521 TABLE 521 WERFEN, S.A.: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.522 TABLE 522 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • 15.523 TABLE 523 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • 15.524 TABLE 524 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024
  • 15.525 TABLE 525 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • 15.526 TABLE 526 CHEMBIO DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • 15.527 TABLE 527 CHEMBIO DIAGNOSTICS, INC.: PRODUCTS OFFERED
  • 15.528 TABLE 528 SURMODICS, INC.: COMPANY OVERVIEW
  • 15.529 TABLE 529 SURMODICS, INC.: PRODUCTS OFFERED
  • 15.530 TABLE 530 MERCK KGAA: COMPANY OVERVIEW
  • 15.531 TABLE 531 MERCK KGAA: PRODUCTS OFFERED
  • 15.532 TABLE 532 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.: COMPANY OVERVIEW
  • 15.533 TABLE 533 CANVAX: COMPANY OVERVIEW
  • 15.534 TABLE 534 PRESTIGE DIAGNOSTICS: COMPANY OVERVIEW
  • 15.535 TABLE 535 ADALTIS S.R.L.: COMPANY OVERVIEW
  • 15.536 TABLE 536 RANDOX LABORATORIES LTD.: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 IVD REAGENTS MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 IVD REAGENTS MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 6 IVD REAGENTS MARKET: TOP-DOWN APPROACH
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 IVD REAGENTS MARKET, BY TYPE, 2024–2029 (USD MILLION)
  • FIGURE 9 IVD REAGENTS MARKET, BY TECHNOLOGY, 2024–2029 (USD MILLION)
  • FIGURE 10 IVD REAGENTS MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
  • FIGURE 11 IVD REAGENTS MARKET, BY TEST TYPE, 2024–2029 (USD MILLION)
  • FIGURE 12 IVD REAGENTS MARKET, BY END USER, 2024–2029 (USD MILLION)
  • FIGURE 13 IVD REAGENTS MARKET, BY REGION, 2024–2029 (USD MILLION)
  • FIGURE 14 INCREASING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 15 CHINA TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 16 US AND LABORATORY TESTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN IVD REAGENTS MARKET IN 2023
  • FIGURE 17 CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 18 IVD REAGENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 19 CRITICAL IMPACT AREAS OF IVD REAGENTS
  • FIGURE 20 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 21 IVD REAGENTS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 22 IVD REAGENTS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 23 IVD REAGENTS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 24 IVD REAGENTS MARKET: INVESTMENT AND FUNDING SCENARIO, 2019−2024
  • FIGURE 25 IVD REAGENTS MARKET: PATENT ANALYSIS, JANUARY 2014–MARCH 2024
  • FIGURE 26 IVD REAGENTS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IVD REAGENTS, BY END USER
  • FIGURE 28 KEY BUYING CRITERIA FOR IVD REAGENTS, BY END USER
  • FIGURE 29 NORTH AMERICA: IVD REAGENTS MARKET SNAPSHOT
  • FIGURE 30 ASIA PACIFIC: IVD REAGENTS MARKET SNAPSHOT
  • FIGURE 31 IVD REAGENTS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD MILLION)
  • FIGURE 32 IVD REAGENTS MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
  • FIGURE 33 FINANCIAL METRICS
  • FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, (2021–2023)
  • FIGURE 35 IVD REAGENTS MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 36 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 IVD REAGENTS MARKET: COMPANY FOOTPRINT
  • FIGURE 38 IVD REAGENTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 42 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)
  • FIGURE 43 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 44 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 45 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 46 BD: COMPANY SNAPSHOT (2023)
  • FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 50 QIAGEN N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 51 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 52 REVVITY: COMPANY SNAPSHOT (2023)
  • FIGURE 53 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 54 GRIFOLS S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 WERFEN, S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 57 CHEMBIO DIAGNOSTICS, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 58 SURMODICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT (2023)

To determine the current size of the IVD reagents market, this study engaged in four main activities. A comprehensive study was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The next stage involved conducting primary research to confirm these conclusions, assumptions, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. The market sizes of segments and subsegments were then estimated using data triangulation techniques and market breakdown.

The four steps involved in estimating the market size are

Secondary Research

Within the secondary data collection process, a range of secondary sources were reviewed so as to identify and gather data for this study, including regulatory bodies, databases (World Bank, World Health Organization, Centers for Disease Control and Prevention, and the US Food and Drug Administration); corporate filings (annual reports, SEC filings, investor presentations, and financial statements); research journals; press releases; and trade, business, and professional associations.

Primary Research

A thorough method was used in the primary research phase, which involved interviewing a wide range of sources from the supply and demand sides. The purpose of these interviews was to obtain the quantitative and qualitative information needed to put up this report. The main sources of information were industry experts from both core and related sectors, as well as preferred service provider, pioneers in technology, and organizations involved in every aspect of this industry's value chain. A variety of primary respondents, including important industry stakeholders, subject-matter experts, C-level executives from crucial market companies, and industry advisers, were carefully questioned in-depth. The goal was to gather and validate important qualitative and quantitative insights and to conduct a thorough assessment of future possibilities.

IVD Reagents Market

Note 1: Other designations include sales, marketing, and product managers.

Note 2: Tiers are defined based on a company’s total revenue. As of 2024, Tier 1= >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
Enzene Biosciences Ltd. Scientist
Danaher Corporation Director of Research & Development
Thermo Fisher Scientific Inc. Sales Manager

Market Size Estimation

All major product providers offering various products and services were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value of the IVD reagents market was also split into various segments and subsegments at the region and country level based on:

  • Offering mapping of various service provider for each type in the IVD reagents market at the regional and country level
  • Relative adoption pattern of each IVD reagents market among key application segments at the regional and/or country-level
  • Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
  • Detailed secondary research to gauge the prevailing market trends at the regional and/or country level
IVD Reagents Market

Data Triangulation

After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

In vitro diagnostic (IVD) reagents are chemicals or substances used to detect, measure, or produce a reaction with components of a sample in an IVD test. They are essential for accurately detecting biological markers or analytes in samples.

Stakeholders

  • IVD Reagents Manufacturers
  • Pathologists and Pathology Laboratories
  • Distributors of IVD Products
  • Hospitals and Clinics
  • Healthcare Institutions
  • Research Institutes
  • Market Research and Consulting Firms
  • Venture Capitalists and Investors

Report Objectives

  • To define, describe, segment, and forecast the global IVD reagents market by type, technology, application, test type, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micro markets with respect to individual growth trends, prospects, and contributions to the overall IVD reagents market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and the GCC Countries
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in IVD Reagents Market

DMCA.com Protection Status